Insights and Analysis
AI-washing – when AI hype becomes a litigation risk
AI-washing – when AI hype becomes a litigation risk
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on extending the recognition of EU CE marked devices in Great Britain indefinitely. The consultation seeks feedback on proposals that would allow CE marked devices to continue to be placed on the Great Britain market beyond the current transitional period, which is due to end on 30 June 2030 for most devices. The proposals reflect the MHRA's commitment to balancing regulatory flexibility with patient safety and market access, and support the government's aim for the UK to become one of the top three fastest countries in Europe for access to MedTech by 2030.
The consultation sets out three main proposals:
If implemented, these proposals would provide manufacturers with ongoing flexibility to use either the CE or UKCA route to market in Great Britain (i.e. England, Scotland and Wales; EU MDD/MDR and IVDD/MDR continue to apply directly in Northern Ireland), reducing the regulatory burden and costs for manufacturers marketing devices across both the EU and UK that already hold CE certification.
The MHRA would also need to consider further changes to ensure sufficient regulatory oversight of CE marked devices on the Great Britain market, for example access to surveillance audits and technical files.
Manufacturers are encouraged to consider the impact of the proposals on their product portfolio and current regulatory strategy, and to contribute their views to the consultation.
The consultation is open until 10 April 2026 and responses will inform the development of a statutory instrument to implement the proposed changes into law as an amendment to the Medical Devices Regulations 2002.
Authored by Jane Summerfield, Bonella Ramsay, Alexandra Wood, and Bea Watts.
This article is the fourteenth in our new thought leadership series, “DigiCure: Legal insights at the intersection of Technology and Life Sciences and Health Care,” which aims to help you stay informed about the broad array of legal and regulatory issues affecting companies operating at the intersection of the technology and life sciences & health care sectors. From using AI in clinical studies, to evolving patient data concerns, to the entire digital health product lifecycle, our team will discuss novel issues arising in all parts of the world, including unique deal-making, litigation, and compliance concerns. Ensure you are subscribed to Our Thinking to receive these new insights!